Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 496 results for 2011

  1. Further research into the comparative efficacy and safety of different surgical and ablative treatments would be useful.

    cryotherapy for renal cancer Number IPG405 Date issued August 2011 Other details Is this a recommendation for the use

  2. Further research into whether ticagrelor is particularly beneficial in any clinical or biological subgroups would be useful.

    coronary syndromes Number TA236 Date issued October 2011 Other details Is this a recommendation for the use

  3. What risk factors predict the onset of substance misuse in young people with psychosis?

    in healthcare settings Number CG120 Date issued March 2011 Other details Is this a recommendation for the use

  4. Further studies on the clinical effectiveness of mifamurtide when combined with the chemotherapy typical of UK clinical practice would be useful to determine the size of the effect of mifamurtide.

    treatment of osteosarcoma Number TA235 Date issued October 2011 Other details Is this a recommendation for the use

  5. Are psychosocial interventions clinically and cost effective when compared with standard care for people with psychosis and coexisting substance misuse?

    in healthcare settings Number CG120 Date issued March 2011 Other details Is this a recommendation for the use

  6. Are environmental interventions clinically and cost effective when compared with standard care for people with psychosis and coexisting substance misuse?

    in healthcare settings Number CG120 Date issued March 2011 Other details Is this a recommendation for the use

  7. NICE highlighted the importance of collecting further data within registries of patients receiving biological treatments for psoriatic arthritis to obtain information on long-term outcomes, including adverse events.

    of psoriatic arthritis Number TA220 Date issued April 2011 Other details Is this a recommendation for the use

  8. Research should be carried out to compare the clinical effectiveness of bendamustine with chlorambucil at the higher dose used in the Chronic Lymphocytic Leukaemia Trial 4 (CLL4).

    lymphocytic leukaemia Number TA216 Date issued February 2011 Other details Is this a recommendation for the use

  9. What service delivery models allow people with psychosis and coexisting substance misuse to remain living outside hospital?

    in healthcare settings Number CG120 Date issued March 2011 Other details Is this a recommendation for the use

  10. Is clozapine clinically and cost effective when compared with other pharmacological interventions for people with psychosis and coexisting substance misuse?

    in healthcare settings Number CG120 Date issued March 2011 Other details Is this a recommendation for the use

  11. What and how should training be provided to healthcare professionals working with people with psychosis and substance misuse?

    in healthcare settings Number CG120 Date issued March 2011 Other details Is this a recommendation for the use

  12. Lung cancer in adults (QS17)

    This quality standard covers diagnosing and managing lung cancer in adults. It describes high-quality care in priority areas for improvement.

  13. How do financial factors (including incentives, pricing and taxation of food and incentives, and pricing for physical activity opportunities) affect food and physical activity choices?

    community-level interventions Number PH35 Date issued May 2011 Other details Is this a recommendation for the use

  14. Is providing treatment for psychosis and substance misuse services within staffed accommodation more cost-effective than a combination of hospital and home treatment?

    in healthcare settings Number CG120 Date issued March 2011 Other details Is this a recommendation for the use

  15. Research is needed on the impact of treating Alzheimer's disease on mortality and institutionalisation, and to assess the relationship between disease progression and carer utility (quality of life).

    Alzheimer's disease Number TA217 Date issued March 2011 Other details Is this a recommendation for the use